A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects

NCT06252961

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Enrollment	99 participants

Key Eligibility Criteria

Inclusion (6)

- Consent informed, written, signed and dated
- Women or men aged 18 to 65 years inclusive
- Carrier of L. loa microfilaremia
- Body weight e 40 kg in women and e 45 kg in men; and less than 90 kg
- In good health, as determined by medical questionnaire and general clinical examination

... and 1 more (see full listing online)

Exclusion (14)

- Participation in any study other than a purely observational study, within the 4 weeks preceding this study (determined by the theoretical date of the first administration of levamisole or placebo)
- Any vaccination within 4 weeks previous to this study
- Infection requiring treatment in the 10 days previous to this study, as determined by the anamnesis during the medical interview (e.g. pulmonary infection , digestive or skin infection; with or without antibiotic treatment)
- Treatment with clozapine, phenothiazines, sulfasalazine, carbamazepine, synthetic antithyroid drugs, ticlopidine, cimetidine, and gold salts: whether it was long-term treatment, or treatment given as a single dose 10 days before the start of treatment for the clinical trial (precaution with regard to the risk of agranulocytosis of immuno-allergic or toxic origin)
- Known immunosuppressive pathology (by self-report)

... and 9 more (see full listing online)

Locations (2 total)

Supervisor, Sibiti, Komono, Republic of the Congo
General Supervisor, Sibiti, Mokassi, Republic of the Congo